Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ATRA Stock Forecast 2026-2027
$4.47
Current Price
$32.23M
Market Cap
Buy 3
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to ATRA Price Targets
+257.9%
To High Target of $16.00
+257.9%
To Median Target of $16.00
+34.2%
To Low Target of $6.00
ATRA Price Momentum
-74.4%
1 Week Change
-75.1%
1 Month Change
-66.0%
1 Year Change
-75.3%
Year-to-Date Change
-76.7%
From 52W High of $19.15
+5.1%
From 52W Low of $4.25
📊 TOP ANALYST CALLS
Did ATRA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Atara is one of their latest high-conviction picks.
Latest ATRA Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, ATRA has a bullish consensus with a median price target of $16.00 (ranging from $6.00 to $16.00). The overall analyst rating is N/A (N/A/10). Currently trading at $4.47, the median forecast implies a 257.9% upside. This outlook is supported by 3 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ATRA Analyst Ratings
3
Buy
2
Hold
0
Sell
ATRA Price Target Range
Low
$6.00
Average
$16.00
High
$16.00
Current: $4.47
Latest ATRA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ATRA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 19, 2025 | Canaccord Genuity | John Newman | Buy | Maintains | $25.00 |
| Mar 11, 2025 | Canaccord Genuity | John Newman | Buy | Maintains | $17.00 |
| Jan 28, 2025 | HC Wainwright & Co. | Robert Burns | Neutral | Reiterates | $N/A |
| Jan 22, 2025 | HC Wainwright & Co. | Robert Burns | Neutral | Reiterates | $N/A |
| Jan 17, 2025 | Canaccord Genuity | John Newman | Buy | Maintains | $17.00 |
| Dec 20, 2024 | Rodman & Renshaw | Tony Butler | Buy | Initiates | $25.00 |
| Nov 13, 2024 | Canaccord Genuity | John Newman | Buy | Maintains | $21.00 |
| Aug 21, 2024 | HC Wainwright & Co. | Robert Burns | Neutral | Reiterates | $N/A |
| Aug 16, 2024 | Mizuho | Salim Syed | Outperform | Upgrade | $18.00 |
| Aug 13, 2024 | Canaccord Genuity | John Newman | Buy | Maintains | $13.00 |
| Jul 17, 2024 | Goldman Sachs | Tommie Reerink | Sell | Maintains | $11.00 |
| May 22, 2024 | HC Wainwright & Co. | Robert Burns | Neutral | Reiterates | $N/A |
| Apr 1, 2024 | Stifel | Benjamin Burnett | Hold | Maintains | $2.30 |
| Nov 10, 2023 | Goldman Sachs | Tommie Reerink | Sell | Maintains | $0.50 |
| Nov 9, 2023 | Evercore ISI Group | Michael DiFiore | In-Line | Downgrade | $N/A |
| Nov 9, 2023 | Mizuho | Salim Syed | Neutral | Downgrade | $1.00 |
| Nov 9, 2023 | HC Wainwright & Co. | Robert Burns | Neutral | Downgrade | $N/A |
| Sep 26, 2023 | HC Wainwright & Co. | Buy | Reiterates | $28.00 | |
| Aug 21, 2023 | Citigroup | Yigal Nochomovitz | Sell | Maintains | $1.40 |
| Aug 9, 2023 | EF Hutton | Anthony Butler | Buy | Reiterates | $25.00 |
Atara Biotherapeutics, Inc. (ATRA) Competitors
The following stocks are similar to Atara based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Atara Biotherapeutics, Inc. (ATRA) Financial Data
Atara Biotherapeutics, Inc. has a market capitalization of $32.23M with a P/E ratio of 1.5x. The company generates $151.93M in trailing twelve-month revenue with a 15.4% profit margin.
Revenue growth is -91.4% quarter-over-quarter, while maintaining an operating margin of -102.7% and return on equity of +87.8%.
Valuation Metrics
Market Cap
$32.23M
Enterprise Value
$45.64M
P/E Ratio
1.5x
PEG Ratio
0.0x
Price/Sales
0.2x
Growth & Margins
Revenue Growth (YoY)
-91.4%
Gross Margin
+96.7%
Operating Margin
-102.7%
Net Margin
+15.4%
EPS Growth
-91.4%
Financial Health
Cash/Price Ratio
+42.6%
Current Ratio
1.0x
Debt/Equity
-0.5x
ROE
+87.8%
ROA
+30.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Atara Biotherapeutics, Inc. (ATRA) Business Model
About Atara Biotherapeutics, Inc.
What They Do
Develops innovative therapies for serious diseases.
Business Model
The company focuses on T-cell immunotherapy to create treatments for cancer and autoimmune diseases. It generates revenue through the development and commercialization of its proprietary therapies, leveraging its EBV T-cell platform and allogeneic T-cell therapies to address significant unmet medical needs.
Additional Information
Atara Biotherapeutics is positioned in the growing cell therapy sector and is actively involved in research and development to advance immunotherapy, offering promising solutions for patients facing serious health challenges.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
38
CEO
Dr. Anhco Nguyen Ph.D.
Country
United States
IPO Year
2014
Website
www.atarabio.comAtara Biotherapeutics, Inc. (ATRA) Latest News & Analysis
Latest News
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)
2 days ago
Quick Summary
Atara Biotherapeutics received a Complete Response Letter from the FDA for its EBVALLO™ (tabelecleucel) Biologics License Application, impacting its development for cancer and autoimmune diseases.
Why It Matters
The FDA's Complete Response Letter for Atara Biotherapeutics' EBVALLO™ may hinder the company's market potential and delay revenue generation, impacting stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress
2 months ago
Quick Summary
Atara Biotherapeutics reported Q3 2025 financial results, highlighting progress in T-cell immunotherapy, including FDA updates on Tabelecleucel (Ebvallo™) for PTLD.
Why It Matters
Atara Biotherapeutics' financial results and updates on Tabelecleucel's FDA status signal potential growth and market opportunities, impacting stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Atara Biotherapeutics (ATRA) shares rose on higher trading volume, but earnings estimate revisions indicate potential weakness ahead.
Why It Matters
The surge in Atara Biotherapeutics' share price amid high volume may signal short-term interest, but weak earnings revisions indicate potential long-term challenges for the stock.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Tabelecleucel's BLA is under FDA Priority Review as a potential first therapy for EBV+ PTLD, with a decision expected by January 10, 2026. Pierre Fabre now manages all related activities.
Why It Matters
The FDA's Priority Review of tabelecleucel signals potential market entry for a novel therapy, influencing investor sentiment on Pierre Fabre's stock and Atara Biotherapeutics' future prospects.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Four biotechnology stocks have entered the top 10th percentile for momentum ranking, indicating significant week-on-week technical strength and positive price movement.
Why It Matters
Strong momentum in biotechnology stocks indicates potential for continued growth, attracting investors seeking high returns and signaling positive market sentiment in the sector.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Atara Biotherapeutics (ATRA) shares rose with above-average trading volume, but recent earnings estimate revisions may not lead to further price increases soon.
Why It Matters
Atara Biotherapeutics' stock surge with high trading volume signals heightened interest, but mixed earnings estimates suggest potential volatility ahead.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About ATRA Stock
What is Atara Biotherapeutics, Inc.'s (ATRA) stock forecast for 2026?
Based on our analysis of 11 Wall Street analysts, Atara Biotherapeutics, Inc. (ATRA) has a median price target of $16.00. The highest price target is $16.00 and the lowest is $6.00.
Is ATRA stock a good investment in 2026?
According to current analyst ratings, ATRA has 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.47. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ATRA stock?
Wall Street analysts predict ATRA stock could reach $16.00 in the next 12 months. This represents a 257.9% increase from the current price of $4.47. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Atara Biotherapeutics, Inc.'s business model?
The company focuses on T-cell immunotherapy to create treatments for cancer and autoimmune diseases. It generates revenue through the development and commercialization of its proprietary therapies, leveraging its EBV T-cell platform and allogeneic T-cell therapies to address significant unmet medical needs.
What is the highest forecasted price for ATRA Atara Biotherapeutics, Inc.?
Price targets from Wall Street analysts for ATRA are not currently available. The stock is trading at $4.47.
What is the lowest forecasted price for ATRA Atara Biotherapeutics, Inc.?
The lowest price target for ATRA is $6.00 from at , which represents a 34.2% increase from the current price of $4.47.
What is the overall ATRA consensus from analysts for Atara Biotherapeutics, Inc.?
The overall analyst consensus for ATRA is bullish. Out of 11 Wall Street analysts, 3 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $16.00.
How accurate are ATRA stock price projections?
Stock price projections, including those for Atara Biotherapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 6:16 AM UTC